This is a non-randomized, open label, multi-site, single dose, Phase 1 study in up to 29 adults with Severe Sickle Cell Disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) using LentiGlobin BB305 Drug Product.